T1	Participants 56 128	metastatic and/or unresectable malignant gastrointestinal stromal tumors
T2	Participants 351 454	patients with CD117(+) unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs)
T3	Participants 606 639	patients with progressive disease
T4	Participants 793 861	European Organization for Research and Treatment of Cancer (n = 946)
T5	Participants 883 917	Southwest Oncology Group (n = 746)
